Sequencing Bispecifics and BCMA-Targeted Therapies in R/R MM
Panelists discuss how bispecifics are sequenced with other B-cell maturation antigen (BCMA)–targeted therapies, such as chimeric antigen receptor (CAR) T cells or antibody drug conjugates (ADCs), and whether early vs late relapse impacts treatment strategies for relapsed/refractory multiple myeloma (R/R MM), with emphasis on how biological and clinical factors influence decision-making.
EP: 1.Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MM
EP: 2.Tailoring Induction Therapy in Newly Diagnosed Transplant-Eligible MM: Key Considerations
EP: 3.AURIGA Trial Highlights: Daratumumab + Lenalidomide Maintenance in Newly Diagnosed MM
EP: 4.Transplant-Ineligible NDMM: Updates from CEPHEUS and IMROZ at ASH 2024
EP: 5.Bispecifics in R/R MM: Key Data and Clinical Implications From ASH 2024 and Ongoing Trials
EP: 6.Strategic Use of Bispecific Antibodies in R/R MM
EP: 7.Sequencing Bispecifics and BCMA-Targeted Therapies in R/R MM
EP: 8.Integrating Bispecific Antibodies Into Clinical Practice
EP: 9.Looking Ahead: Major Clinical Advancements in Myeloma From ASH 2024 and What’s to Come in 2025
EP: 10.Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma
Video content above is prompted by the following:
- How do you approach sequencing bispecifics with other BCMA-targeted therapies, such as CAR T cells or ADCs?
- Does the time frame of relapse—early vs late—alter your treatment sequencing strategies for R/R MM patients?
- How do the biological and clinical characteristics of early vs late relapse influence your decision-making process?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
